Analytical Data
-
Gene name
IFN-alpha 10/IFNA10
- Application
-
Alternative Names
Interferon alpha-6LInterferon alpha-C ;LeIF C
-
Species
Human
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01566
-
Expression Region
24-189aa
-
Protein Length
Partial
-
Molecular Weight
21.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Interferon-alpha 10 (IFN-alpha 10, or IFNA10) is a cytokine belonging to the type I interferon family, which plays a crucial role in the immune response against viral infections and tumors. IFNA10 exhibits antiviral, antiproliferative, and immunomodulatory properties, making it a subject of interest in biomedical research. Its unique expression patterns and functions suggest potential therapeutic applications in various diseases, particularly in cancer and viral infections such as HIV and hepatitis. Research has focused on the recombinant production of IFNA10 to evaluate its efficacy and safety as a therapeutic agent. Advances in biotechnology, such as genetic engineering and recombinant DNA technology, have facilitated the generation of high-purity IFNA10 proteins. Studies have demonstrated that IFNA10 can enhance the immune response by activating immune cells, promoting apoptosis in infected or malignant cells, and upregulating the expression of major histocompatibility complex (MHC) molecules. However, challenges remain in delivering IFNA10 effectively to the target sites and minimizing potential side effects. Ongoing research aims to elucidate the mechanisms of action of IFNA10, explore its potential in combination therapies, and develop novel delivery systems to enhance its therapeutic efficacy.
